Cyllene's €33M Bet: Can Gene Therapy Solve Chronic Bladder Dysfunction?

PARIS, FRANCE – July 07, 2026 – In a move that signals growing confidence in the next wave of genetic medicines, Cyllene Therapeutics has secured a €33 million Series C financing round. The investment, co-led by GordonMD Global Investments® LP and M Ventures, the corporate venture arm of Merck, marks a pivotal moment for the Parisian biotech, which simultaneously shed its former name, EG 427, to reflect its maturation into a late-stage clinical entity.

The capital infusion is set to propel the company’s lead candidate, EG110A, through advanced clinical trials for severe neuro-urological disorders. More broadly, it represents a significant wager on a technology platform that could redefine treatment paradigms far beyond the bladder, using a re-engineered herpes virus to deliver pinpoint therapeutic strikes against chronic neurological diseases.

A Precision Strike on a Chronic Affliction

For the millions suffering from neurogenic detrusor overactivity (NDO) and the more common overactive bladder (OAB), life is often dictated by a constant, urgent need. The global OAB treatment market, valued at nearly $3.8 billion, is dominated by therapies that offer incremental relief at the cost of significant burdens. Daily pills can carry systemic side effects like dry mouth and constipation, while injections of botulinum toxin (Botox) into the bladder muscle, though effective, require repeat procedures every six to nine months and risk causing urinary retention.

Cyllene Therapeutics is proposing a radical departure from this cycle. Its lead candidate, EG110A, is a gene therapy designed as a potential one-and-done treatment. The therapy's early clinical results are striking. In an ongoing Phase 1/2 study (NCT06596291) for patients with NDO from spinal cord injuries, initial data showed a greater than 88% reduction in urinary incontinence episodes, with effects sustained for at least nine months post-treatment. This promising data earned EG110A a Fast Track designation from the U.S. FDA, highlighting the profound unmet need for durable and less burdensome solutions.

The true innovation lies in the company's HERMES platform. EG110A uses a non-replicating Herpes Simplex Virus Type 1 (nrHSV-1) vector as a delivery vehicle. This modified virus is engineered to be non-replicating and safe, leveraging its natural ability to target nerve cells. After being injected into the bladder wall, the vector travels to the sensory neurons responsible for signaling bladder fullness and overactivity. There, it delivers its payload: a gene that selectively silences the overactive type C sensory neurons without affecting normal bladder muscle function. This precision targeting is the key to its strong efficacy and favorable safety profile, which has so far been free of systemic side effects.

Why Top Investors Are Backing a Novel Vector

The €33 million financing is more than just fuel for the next clinical phase; it's a validation of the underlying HERMES platform. The involvement of specialized investors like GordonMD and the strategic venture arm M Ventures underscores a belief that Cyllene's technology is fundamentally different.

“Cyllene Tx exemplifies the kind of bold, science-driven innovation for high unmet medical needs we seek to support,” said Björn Kuhl, Principal at M Ventures. He described the HERMES platform as a “fundamentally differentiated approach to genetic medicine” with broad potential. This differentiation is critical. While Adeno-Associated Virus (AAV) vectors have dominated the gene therapy landscape, they are constrained by a small payload capacity, limiting the complexity of the genetic instructions they can carry. Furthermore, AAV therapies can trigger immune responses that often prevent redosing.

Cyllene's nrHSV-1 platform circumvents these limitations. Its large payload capacity—capable of carrying over 20,000 base pairs of genetic code—allows for the delivery of more complex therapeutic genes and sophisticated regulatory elements. Crucially, its low immunogenicity profile opens the door to potential repeat dosing, a major strategic advantage for treating chronic or progressive diseases. The virus’s ability to persist in nerve cells without integrating into the host's genome also provides a durable effect while mitigating the risk of insertional mutagenesis.

“The preliminary clinical results of EG110A support the application of precision therapeutics within neuro-urology,” noted Craig Gordon, MD, of GordonMD. His firm’s investment is predicated on the platform's potential for “global expansion, extending its pipeline into major neurological indications, including pain and migraine.” This long-term vision, shared by existing investors like Andera Partners and Bpifrance Investissement who also participated in the round, is what separates a promising drug from a transformative technology platform.

A New Name for a New Chapter

The company’s transition from EG 427 to Cyllene Therapeutics is a deliberate act of strategic branding. The new name, a reference to Mount Cyllene, the mythical birthplace of Hermes, forges a direct link to its core HERMES technology. This move signals a pivot from a discreet R&D-focused entity to a mature, late-stage clinical company preparing for a global stage.

With the new funding, Cyllene plans to initiate a pivotal Phase 2b/3 study for EG110A in 2027. Success there would put it on a direct path to market. In parallel, the company is already laying the groundwork for expansion, with plans to investigate EG110A for the much larger overactive bladder market and to leverage the HERMES platform to develop new drug candidates for other prevalent neurological conditions.

This rebranding and financial reinforcement position Cyllene Therapeutics at the forefront of a new class of genetic medicines. The company is no longer just developing a single product; it is building a versatile therapeutic engine with the potential to deliver durable, targeted treatments for some of medicine's most persistent and challenging chronic diseases.